CytomX Therapeutics, Inc. (NASDAQ:CTMX) Under Analyst Spotlight


Wedbush also issued estimates for CytomX Therapeutics' Q3 2017 earnings at ($0.36) EPS, Q4 2017 earnings at ($0.24) EPS, FY2017 earnings at ($1.51) EPS, Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.24) EPS, Q3 2018 earnings at ($0.27) EPS, Q4 2018 earnings at ($0.30) EPS, FY2018 earnings at ($1.02) EPS, FY2019 earnings at ($1.53) EPS, FY2020 earnings at ($3.48) EPS and FY2021 earnings at ($2.31) EPS.

A number of brokerages have issued reports on CTMX.

Amgen (AMGN) along with CytomX Therapeutics, (CTMX) reported that the companies have entered into a strategic collaboration in immuno-oncology. Oppenheimer initiated it with "Outperform" rating and $17 target in Monday, November 2 report.

In related news, major shareholder Robert I. Tepper sold 24,777 shares of the firm's stock in a transaction that occurred on Wednesday, October 4th. As per Tuesday, January 3, the company rating was downgraded by Oppenheimer. (NASDAQ:CTMX) recently. President and CEO Sean A. Mccarthy sold 19,120 shares at an average price of $24.13 on Wednesday the 4th. Days to cover decreased -2.0 to 5.0 and the percentage of shorted shares is 0.03% as of August 31.

There are many different tools to determine whether a company is profitable or not.

About 550,997 shares traded or 33.08% up from the average. Should the company pursue these targets, CytomX will be able to receive up to $950 million in additional upfront and milestone payments as well as royalties from any resulting products. The Price to Cash Flow for CytomX Therapeutics, Inc.

Ghana begin World Cup with a win
In a high-octane clash, Colombia failed to breach the tall, physical and organised defensive wall of the Africans. Ghana will face the US in their next group game on Monday at the Jawaharlal Nehru Stadium in New Delhi .

Amber Alert issued for Richardson toddler
Anyone with information about the girl's location is asked to contact the Richardson Police Department at 972-744-4800. They've believed to be driving a 2008 Silver Ford Fusion with the license plate number 7RLR145.

Western Michigan beats Buffalo 71-68 in a record-tying 7 overtimes
Ernsberger had an incredible night in the insane win, but he'll probably tell his sister to relax a bit next time. WMU tight end Donnie Ernsberger (Battle Creek Lakeview) caught a 14-yard touchdown pass in the first overtime.

Analysts expect next quarter's EPS to be $-0.41 and the next full year EPS is anticipated to be $-1.38. California State Teachers Retirement System boosted its stake in shares of CytomX Therapeutics by 27.8% in the second quarter. The return on equity ratio or ROE stands at -84.6 percent while most common profitability ratio return on investment (ROI) was -75.9 percent. The company had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million. Equities research analysts predict that CytomX Therapeutics will post ($1.47) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this piece of content on another site, it was stolen and republished in violation of worldwide copyright and trademark law.

Amid volatile financial markets and the presidential election, various investment brokerages have made amendments to their price targets and ratings on shares of CytomX Therapeutics, Inc. $32.80's average target is 49.02% above currents $22.01 stock price. TAPM's SI was 14,900 shares in October as released by FINRA. For example, if there is good news like a positive earnings announcement, the demand for a stock may increase, raising the price from the previous day's close. The disclosure for this sale can be found here. Logan Capital Management Inc sold 6,995 shares as Abbvie Inc. Gluck now owns $5,564,424 of the stock according to the SEC filing.

Several hedge funds and other institutional investors have recently modified their holdings of CTMX. They now have a $34 PT on the company. Amgen will lead later development and the sales side, should it gain approval, with "global late-stage development costs shared between the two companies". As of quarter end Opaleye Management Inc. had bought 120,000 shares growing its stake by 35.3%. Goldman Sachs Group Inc. acquired a new position in CytomX Therapeutics in the 1st quarter worth approximately $190,000. Iguana Healthcare Management, LLC controls 60,000 shares valued at $930,000.

Here is a rundown on some insider market activity for CytomX Therapeutics, Inc.

"Probody-based T-cell engaging bispecific antibodies offer significant potential in treating cancers by employing localized therapeutic activity within tumor tissue", said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics. "Development of Probody-based T-cell engaging bispecifics further validates the broad applicability of the Probody platform in addressing unmet needs in oncology".